Biotech Conference coverage Day 3 Session 2 - MannKind Corporation

MNKD (update): Management says Afrezza is gaining momentum, while an auto-injector is expected to launch broadly in Q4 and could broaden MannKind’s respiratory and cardiometabolic business. Reported new-patient growth doubled from June to July and again into August, with refills near or above expectations. The key test is whether these commercial drivers endure and the auto-injector expands the market rather than merely converts users; United Therapeutics partner concentration remains a major risk.

Read full article (2 min)